Behavioural effects and regulation of PKCα and MAPK by huprine X in middle aged mice

The behavioural effects of huprine X, a new anticholinesterasic inhibitor, as well as its effects on the regulation of protein kinase C (PKC), mitogen activated protein kinase (MAPK) and α-secretase (ADAM10 and TACE/ADAM17) related to amyloid precursor protein (APP) processing remain to be establish...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology, biochemistry and behavior Vol. 95; no. 4; pp. 485 - 493
Main Authors: Ratia, M., Giménez-Llort, L., Camps, P., Muñoz-Torrero, D., Clos, MªV., Badia, A.
Format: Journal Article
Language:English
Published: Kidlington Elsevier Inc 01-06-2010
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The behavioural effects of huprine X, a new anticholinesterasic inhibitor, as well as its effects on the regulation of protein kinase C (PKC), mitogen activated protein kinase (MAPK) and α-secretase (ADAM10 and TACE/ADAM17) related to amyloid precursor protein (APP) processing remain to be established. In the present work, 12 month old 126/Sv × C57b/6 male mice which received chronic i.p. treatment with either saline, huprine X (0.04 µmol kg − 1) or huprine X (0.12 µmol kg − 1), were submitted to a battery of behavioural tests and thereafter the brains were dissected to study the neurochemical effects induced by huprine X. The results show that, in a dose dependent manner, huprine X facilitates learning and memory in the Morris water maze and improves some indicators of emotionality without inducing adverse effects, affecting motor activity nor anxiety-like behaviours, as measured in the open-field and corner tests. Moreover activation of downstream PKC/MAPK signaling pathways may underly these behavioural effects as well as the stimulation of the non-amyloidogenic processing of APP. Results obtained herein using a sample of aged animals strongly suggest that huprine X constitutes a promising therapeutic agent for the treatment of cholinergic dysfunction underlying aging and/or dementias.
ISSN:0091-3057
1873-5177
DOI:10.1016/j.pbb.2010.03.013